More scientists will get jobs this year, says survey
The UK science labour market has been resilient to the economic downturn, with more skilled scientists being recruited and a significant increase in requirements predicted for contract staff during the next 12 months, a survey has revealed.
SRG's 2009-2010 UK Science Labour Trends Survey questioned organisations in the chemicals, pharmaceuticals, biotechnology and healthcare, oil, petrochemical and food industries.
The survey had 554 respondents, who revealed that biotechnology was second to oil/gas/petrochemicals in employing the most permanent staff in 2009 compared with 2008. Biotechnology is also now near the top in terms of the number of permanent staff it plans to hire across all regions in the UK.
This positive trend continues for contract scientific staff, although the levels of recruitment here are expected to remain stable rather than increase during 2010.
Regionally, the South West and Wales are finding it easiest to recruit permanent scientific staff, while Scotland is struggling. Wales is the one region in which significantly more companies are using fewer staff than a year ago.
The Midlands has seen the biggest downward trend in the use of temporary scientists year on year.
Ena Vieira, biotechnology industry specialist for UK scientific personnel recruitment agency SRG said: "With the unstable economic situation over the last 12 months, biotech companies have become even more focused on the commercial returns of their products. This has led to a trend emerging, showing that they are now seeking to recruit more commercially focused staff while still requiring them to have suitable scientific skills."
She added: "The results of our latest survey clearly show that the outlook for 2010 is looking positive as, from all the sectors surveyed, biotechnology is predicting the second-highest increased permanent staff recruitment during 2010."
You may also like
Manufacturing
Former Catalent Chair and CEO George Fotiades joins eXmoor Pharma board as Chair
Angela Osborne steps back from operational duties and continues as Founder and Board Director, providing strategic continuity as eXmoor builds the leadership depth to support its expanding integrated CDMO model
Manufacturing
BioNTech to cut up to 1860 jobs and end COVID vaccine production in Germany
The German biotech has announced it will cease production at its manufacturing sites in Germany and Singapore in its Q1 earnings report, cutting up to 22% of its workforce in the process as it pivots from COVID-19 vaccines to oncology
Finance
Novo Nordisk raises 2026 guidance after Wegovy pill drives stronger-than-expected Q1 earnings
The firm has reported first-quarter earnings of $7.61bn and revenue of $15.17bn, both ahead of Wall Street forecasts, driven by robust GLP-1 sales and stronger-than-expected performance from its oral Wegovy pill
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Finance
Britain's biotech potential (part II): world-class science, second-class support?
In part one, Manufacturing Chemist explored the UK’s world-class science base and early-stage investment appeal. In this second instalment, attention turns to the structural gaps that are limiting its ability to scale
Finance
Sun Pharma to acquire Organon in $11.75bn deal, expanding global manufacturing and biosimilars reach
The firm will acquire Organon in an all-cash $11.75bn transaction, creating a larger global pharma group with expanded manufacturing capacity, stronger women's health operations and a top-10 biosimilars position